MJMandy Jongbloed

Mandy Jongbloed

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mandy Jongbloed has a total of 57 co-authors. Here are the top co-authors by number of shared publications:

  • Lizza Elisabeth Lucia Hendriks

    Department of Pulmonary Diseases, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, The Netherlands

    6 shared publications
  • Cordula Pitz

    Department of Pulmonary Diseases, Laurentius Hospital, Roermond, The Netherlands

    4 shared publications
  • Ben E.E.M. van Den Borne

    Department of Pulmonary Diseases, Catharina Hospital, Eindhoven, The Netherlands

    3 shared publications
  • Dirk K.M. De Ruysscher

    Department of Radiation Oncology (Maastro Clinic), Maastricht University Medical Center, GROW - Research Institute for Oncology and Reproduction, Maastricht, Netherlands

    3 shared publications
  • Jarno W. J. Huijs

    Department of Pulmonary Diseases, GROW - Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands

    3 shared publications
  • Magdolen Youssef-El Soud

    Department of Pulmonary Diseases, Maxima Medical Center, Eindhoven, The Netherlands

    3 shared publications

Latest Publications

  • Metastatic Trajectories in Non–Small Cell Lung Cancer Guide Local and Systemic Therapies

    by Jonas Willmann, Edward Christopher Dee, Lizza E.L. Hendriks, Nikolaos M. Dimitriou, Mandy Jongbloed, Adam J. Schoenfeld, Alexander Drilon, Karuna Ganesh, Y. Helen Zhang, Jill Feldman, et al.

    Advances in systemic therapy have improved outcomes for metastatic non–small cell lung cancer (NSCLC), yet resistance and progression remain nearly universal. Local therapies such as radiotherapy, surgery, and image-guided ablation can extend disease control in selected patients, but existing classifications—including dynamic models of oligometastatic disease—assign a single state per patient and do not capture lesion-level heterogeneity. We introduce the concept of metastatic trajectories —the spatiotemporal dynamics of response and progression across lesions, organs, and patients—as a framework to characterize intrapatient heterogeneity and inform adaptive treatment strategies. Dimensions of metastatic trajectories include the magnitude and homogeneity of response, mechanisms of resistance, organotropism, and the pattern, site, extent, and pace of progression. This framework shifts the focus from overall disease states to individual lesion behavior over time, enabling reactive strategies based on observed trajectories and anticipatory strategies based on predicted ones. We review the biological foundations of intrapatient heterogeneity—including genomic diversification, nongenetic plasticity, and tumor-microenvironmental adaptation—that drive divergent lesion evolution and treatment response. Emerging biomarkers such as circulating tumor DNA and radiomic signatures, together with integrative genomic and functional imaging approaches, may allow tracking and prediction of trajectory evolution. Standardized reporting parameters are proposed to ensure consistent documentation and facilitate validation across studies. Integrating trajectory-based assessment into clinical practice could refine patient selection for local and systemic therapy, enable biology-informed adaptation of treatment timing and intensity, and provide a foundation for next-generation clinical trials aimed at precision management of metastatic NSCLC.


  • Open Access

    Patterns of progression in patients with synchronous oligometastatic non-small cell lung cancer after systemic and local radical treatment

    by Valentina Bartolomeo, Mandy Jongbloed, Jarno W.J. Huijs, Andrea Riccardo Filippi, Ben E.E.M. van Den Borne, Cordula Pitz, Hester Gietema, Juliette Degens, Magdolen Youssef-El Soud, Michelle Steens, et al.

  • Open Access

    Effect of treatment sequencing on outcome of patients with non-small cell lung cancer with a synchronous solitary extrathoracic metastasis

    by Mandy Jongbloed, Ronald A.M. Damhuis, Wouter H. Van Geffen, Peter de Boer, Jarno W.J. Huijs, Safiye Dursun, Juliette Degens, Ben E.E.M. van Den Borne, Magdolen Youssef-El Soud, Michelle Steens, et al.


  • Association of metabolic tumour volume (MTV) and total lesion glycolysis (TLG) with survival in patients with oligometastatic non-small-cell lung cancer treated with immunotherapy: a multicentre retrospective study

    by Francesca Rita Ogliari, Mandy Jongbloed, Rianne D. W. Vaes, Ruud M. A. Houben, Valentina Bartolomeo, Ben E. E. M. van Den Borne, Juliette Degens, Jarno W. J. Huijs, Cordula Pitz, Michelle Steens, et al.

    Purpose Current guidelines recommend adding local radical therapy (LRT) to systemic treatment in synchronous oligometastatic non-small-cell lung cancer (sOM-NSCLC), but survival data on immunotherapy-based regimens are limited. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) are prognostic in NSCLC, with higher values linked to worse outcomes. This study examines their association with survival in sOM-NSCLC patients treated with immunotherapy. Methods We conducted a multicenter retrospective study including all consecutive patients with [18F]FDG-PET and brain imaging-staged sOM-NSCLC, between 2015 and 2022, who received first-line (chemo)-immunotherapy and had baseline PET-scan available for review. Subgroups were analyzed based on median MTV and TLG values (high vs. low: H-MTV vs. L-MTV, H-TLG vs. L-TLG). Study endpoints were progression-free survival (PFS) and overall survival (OS), according to MTV and TLG distribution (high vs. low), in the overall population (primary endpoint) and in relation to LRT and systemic treatment type (secondary endpoints). Results 105 patients were included, 50% were male and 73% had non-squamous histology, median age was 64.9 years. Median PFS was significantly longer for L-MTV vs. H-MTV (14.73 months (95%CI, 7.06–22.40) vs. 7.63 months (95%CI, 5.73–9.52), p = 0.028), but also LRT was associated with PFS (19.04 months (95%CI, 8.47–29.60) versus 7.46 months (95%CI, 5.25–9.67), p = 0.045), while neither MTV nor TLG had impact on OS. In multivariate analysis, only PD-L1 < 50% and soft tissue metastases remained significantly associated with shorter PFS. Conclusions Baseline MTV is preliminarily associated with PFS in sOM-NSCLC patients treated with immunotherapy, but results are exploratory and need prospective validation in larger cohorts.


  • Open Access

    Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC

    by Mandy Jongbloed, Valentina Bartolomeo, Martina Bortolot, Shahan Darwesh, Jarno W.J. Huijs, Safiye Dursun, Juliette Degens, Ben E.E.M. van Den Borne, Maggy Youssef-El Soud, Marcel Westenend, et al.


  • Open Access

    Cachexia and Sarcopenia in Oligometastatic Non-Small Cell Lung Cancer: Making a Potential Curable Disease Incurable?

    by Valentina Bartolomeo, Mandy Jongbloed, Wouter R. P. H. van de Worp, Ramon Langen, Juliette Degens, Lizza E. L. Hendriks, Dirk K. M. de Ruysscher

    Among patients with advanced NSCLC, there is a group of patients with synchronous oligometastatic disease (sOMD), defined as a limited number of metastases detected at the time of diagnosis. As cachexia and sarcopenia are linked to poor survival, incorporating this information could assist clinicians in determining whether a radical treatment should be administered. In a retrospective multicenter study, including all patients with adequately staged (FDG-PET, brain imaging) sOMD according to the EORTC definition, we aimed to assess the relationship between cachexia and/or sarcopenia and survival. Of the 439 patients that were identified between 2015 and 2021, 234 met the criteria for inclusion and were included. The median age of the cohort was 67, 52.6% were male, and the median number of metastasis was 1. Forty-six (19.7%) patients had cachexia, thirty-four (14.5%) had sarcopenia and twenty-one (9.0%) had both. With a median follow-up of 49.7 months, median PFS and OS were 8.6 and 17.3 months, respectively. Moreover, a trend toward longer PFS was found in patients without cachexia and sarcopenia compared to those with cachexia and/or sarcopenia. In multivariate analysis, cachexia and sarcopenia were not associated with an inferior survival, irrespective of receiving radical treatment. High CRP was associated with inferior survival and could be a prognostic factor, helping the decision of clinicians in selecting patients who may benefit from the addition of LRT. However, despite the homogeneous definition of oligometastatic disease and the adequate staging, our subgroups were small. Therefore, further studies are needed to better understand our hypothesis and generating findings.